| Disease Specific Interactions between Host Protein and DME (HOSPPI) |
| ICD Disease Classification Healthy |
| ICD-11: Healthy |
Click to Show/Hide the Full List of HOSPPI: 2 HOSPPI
|
| Transcription-factor regulation |
| Nuclear receptor family 0 I3 (NR1I3) |
Health |
Activation |
| Uniprot ID |
|
| Interaction Name |
NR1I3-CYP2B6 interaction |
[2] |
| Studied Cell Lines |
Healthy subjects |
| Ensembl ID |
|
| Description |
Nuclear receptor family 0 I3 (NR1I3) is reported to activate the transcription of CYP2B6 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2B6. As a result, the interaction between NR1I3 and CYP2B6 can activate the drug-metabolizing process of Cytochrome P450 2B6. |
| Non-coding RNA regulation |
| hsa-miR-25-3p |
Health |
Suppression |
| miRBase ID |
|
| Interaction Name |
hsa-miR-25-3p--CYP2B6 regulation |
[1] |
| Studied Cell Lines |
HEK293 cell line |
| Description |
hsa-miR-25-3p is reported to suppress CYP2B6 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2B6 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Cytochrome P450 2B6. |
| ICD Disease Classification 02 Neoplasms |
| ICD-11: 2C12 Liver cancer |
Click to Show/Hide the Full List of HOSPPI: 3 HOSPPI
|
| Transcription-factor regulation |
| Activating TF factor 5 (ATF5) |
Liver cancer |
Activation |
| Uniprot ID |
|
| Interaction Name |
ATF5-CYP2B6 interaction |
[3] |
| Studied Cell Lines |
HepG2, Hep3B and Mz cell lines |
| Ensembl ID |
|
| Description |
Activating TF factor 5 (ATF5) is reported to activate the transcription of CYP2B6 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2B6. As a result, the interaction between ATF5 and CYP2B6 can activate the drug-metabolizing process of Cytochrome P450 2B6. |
| Early growth response 1 (EGR1) |
Liver cancer |
Activation |
| Uniprot ID |
|
| Interaction Name |
EGR1-CYP2B6 interaction |
[5] |
| Studied Cell Lines |
Ym17, Yh18 and COS-1 cell lines |
| Ensembl ID |
|
| Description |
Early growth response 1 (EGR1) is reported to activate the transcription of CYP2B6 gene, which leads to an increased expression of the drug-metabolizing enzyme Cytochrome P450 2B6. As a result, the interaction between EGR1 and CYP2B6 can activate the drug-metabolizing process of Cytochrome P450 2B6. |
| DNA methylation |
| DNA methyltransferase (DNMT) |
Liver cancer |
Significant hypermethylation |
| Uniprot ID |
|
| Interaction Name |
DNMT-CYP2B6 interaction |
[4] |
| Studied Cell Lines |
Live tissue |
| Description |
DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP2B6 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cytochrome P450 2B6. As a result, the interaction between DNMT and CYP2B6 can significantly affect the drug-metabolizing process of Cytochrome P450 2B6. |
|
|
|
|
|
|
